Inclusion Body Myositis
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbcuroABC008
AbcuroABC008
AmgenEtanercept
Clinical Trials (3)
Total enrollment: 311 patients across 3 trials
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Start: Feb 2023Est. completion: Nov 2025272 patients
Phase 2/3Completed
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
Start: May 2021Est. completion: Jan 202519 patients
Phase 1Completed
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Start: Apr 2005Est. completion: May 201420 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space